Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Imran, Mohd., Asdaq, Syed Mohammed Basheeruddin, Khan, Shah Alam, Unnikrishnan Meenakshi, Dhanalekshmi, Alamri, Abdulhakeem S., Alsanie, Walaa F., Alhomrani, Majid, Mohzari, Yahya, Alrashed, Ahmed, AlMotairi, Mohammed, Alkhaldi, Eman H., Alorabi, Abeer K., Alshrari, Ahmed Subeh, Tauseef, Mohammad, Abida, Alaqel, Saleh I., Alam, Ozair, Bakht, Md. Afroz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400070/
https://www.ncbi.nlm.nih.gov/pubmed/34451807
http://dx.doi.org/10.3390/ph14080710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400070/
https://www.ncbi.nlm.nih.gov/pubmed/34451807
http://dx.doi.org/10.3390/ph14080710

Ejemplares similares